tbuckley/cabot-search huggingface dataset:
Pegfilgrastim Supports Delivery of BEACOPP Chemotherapy Administered Every 14 Days.
Authors: Andreas Engert, Hartmut Doehner, Anthony D. Ho, Norbert Schmitz, Henning Bredenfeld, Dieter Hoelzer, Beate Klimm, Axel Muenz, Valerie Easton, Pamela Bacon, Volker Diehl
Journal: Blood (2004)
NIMG-54PREOPERATIVE PREDICTION OF IDH1 MUTATION IN GLIOMA TISSUE BY MR SPECTROSCOPY
Authors: Hiroaki Nagashima, Kazuhiro Tanaka, Takashi Sasayama, Naoko Satoh, Yasuhiro Irino, Katsusuke Kyotani, Eiji Kohmura
Journal: Neuro-Oncology (2015)

INTRODUCTION: Mutation in isocitrate dehydrogenase 1 (IDH1) are found in up to 80% of low-grade glioma and secondary glioblastoma. The 2-hydroxyglutaric acid (2HG) specifically produced by mutant IDH1 would be a target to detect IDH1 mutant glioma. Therefore, reliable measurements of 2HG with in vivo MR spectroscopy (MRS) are of clinical interest to develop a noninvasive detection of IDH mutant glioma. MATERIALS AND METHODS: Metabolic profiling including 2HG of tumor targets was assessed by in vivo MRS preoperatively and analyzed with LC-model post-processing. Stereotactic navigation-guided sampling was performed exactly of the corresponding area to the preoperative MRS sampling. Ex vivo 2HG of the samples was quantified by Gas Chromatography Mass spectrometer (GC/MS) and compared with 2HG detected by in vivo MRS. The diagnosis of IDH1 mutant gliomas was confirmed by the immunohistochemical staining and the DNA sequence. RESULTS: Of the 40 patients enrolled in this study, 16(40%) had histologically verified IDH1 mutation. 2HG was exactly measurable by MRS at higher concentration than 1.5mM in 8 of 16 IDH mutated cases (Sensitivity 57% and specificity 92%). Although there were no significantly differences in metabolites of the TCA cycle between IDH1 mutant and wild cases, glutamate and glutamine were significantly lower in the IDH1 mutant group. Additional measurement of glutamate reduced false-negative results to predictive IDH1 mutation. Sensitivity improved to 69% and specificity to 100% (AUC 0.89). CONCLUSIONS: A change of the glutamine metabolism is inferred with IDH1 mutation. Measurement of glutamate may support the potential clinical use of 2HG using MRS as a predictor for IDH1 mutation in glioma because of limiting ability to measure 2HG directly with preoperative MRS.
Everolimus (E) and temsirolimus (T) associated pneumonitis (P) in patients with metastatic renal cell cancer (mRCC): A single-center experience.
Authors: Diana H. Cauley, Bradley J. Atkinson, Chaan S. Ng, Xuemei Wang, Lianchun Xiao, Paul G. Corn, Eric Jonasch, Nizar M. Tannir
Journal: Journal of Clinical Oncology (2012)

401 Background: P is a known adverse effect (AE) of mammalian target-of-rapamycin inhibitors, with a literature reported incidence of 25-45%. The goal of this review was to characterize the incidence, timing, management, and overall survival (OS) of pts treated at our center. Methods: Retrospective review of 332 patients (pts) with complete, evaluable records, who received E and/or T between 6/1/2007 and 10/1/2010. Clinical correlation was made in conjunction with serial radiologic imaging studies. Results: P occurred in 25.2 of E and 8.1 % of T pts. 10.7 of E and 11.1 % of T pts reported no symptoms (sx). 60.7 and 72.2 % reported cough, 67.9 and 61.1 % dyspnea, 17.9 and 5.6 % fever, and 67.9 and 88.9 % fatigue, with E and T, respectively. The median # of sx/pt was 2 and 3; 42.9 and 50 % received steroids, 35.7 and 22.2 % received antibiotics, 21.4 and 27.8 % had a pulmonary consult, and 10.7 and 16.7 % received oxygen, with E and T, respectively. Providers discontinued tx in 75 and 38.9%, continued tx in 17.9 and 27.8%, continued at reduced dose in 0 and 5.6%, held and later dose reduced in 7.1 and 16.7%, and held then resumed at same dose in 0 and 11.1% of pts, with E and T, respectively. The median NCI-CTC P grade was 2 (range 1–3) in both groups. No patients died from P. Conclusions: A higher incidence of P was observed in pts treated with E than T. The finding of improved OS in pts who develop P with E is intriguing and should be further investigated. [Table: see text]
Rearrangements of the MLL Gene Are Influenced by DNA Secondary Structure, Potentially Mediated by Topoisomerase II Binding
Authors: Hongan Le, Sabine Schnyder, Nga Du, Grace Loredo, Sheetal Singh, Shyh-Jen Shih, Laura Michaelis, Christine Bien, Manuel Diaz, Andrew T.M. Vaughan
Journal: Blood (2008)
Characterisation of the Stem and Progenitor Cell Hierarchy in Patients with CMML
Authors: Onima Chowdhury, Petter S Woll, Una Kjällquist, Helen Doolittle, Rikard Erlandsson, Kristina Anderson, Ingunn Dybedal, Adam Mead, Sally-Ann Clark, Mette S. Holm, Peter Hokland, Lars Nilsson, Sten Linnarsson, Eva Hellstrom-Lindberg, Sten Eirik W Jacobsen
Journal: Blood (2014)
Erythropoietic Therapy Does Not Stimulate Tumor Growth in Erythropoietin Receptor (EPOR)-Positive MDA-MB-231 and MCF-7 Breast Carcinoma Models.
Authors: Kenneth R. LaMontagne, Jeannene Butler, Deborah Marshall, Jennifer Tullai, Ze’ev Gechtman, Chassidy Hall, Francis X. Farrell
Journal: Blood (2005)
Oh the irony: Perceptual stability is important for action
Authors: Frank H Durgin
Journal: Behavioral and Brain Sciences (2016)

Abstract I review experiments in which drinking a sugarless drink causes some participants who have low blood sugar from fasting to give lower slant estimates. Ironically, this only occurs to the extent that they believe that they have received sugar and that the sugar was meant to make the hill look shallower; those who received sugar showed no similar effect. These findings support the hypothesis that low blood sugar causes greater participant cooperation – which, in combination with other experimental details, can lead participants to make judgments that can either seem to support the effort hypothesis or contradict it. I also emphasize the importance of perceptual stability in the perception of spatial layout.
Comparative Genomic Analysis of the 5′-Upstream Sequences of von Willebrand Factor and 27 Other Endothelial-Specific Genes Identifies Conserved Noncoding Sequences That Are DNase Hypersensitive.
Authors: John A. Bernat, Alexey S. Kondrashov, Gregory E. Crawford, Francis S. Collins, David Ginsburg
Journal: Blood (2005)
Constitutive Lymphoid Expression of the Nuclear Form of RNase H1 Is Associated with a Developmental Bottleneck at the Pro-B Cell Stage of B Cell Differentiation.
Authors: Lina A. Gugliotti, Kiran B. Sakhuja, Hongsheng Wang, Julia Pinkhasov, Paul E. Love, Susana M. Cerritelli, Herbert Morse, Robert J. Crouch
Journal: Blood (2009)
The Role of Autologous Stem Cell Transplantation (ASCT) in Patients with Advanced Waldenström’s Macroglobulinemia.
Authors: Charalampia Kyriakou, C. Canals, A. Sureda, G. Taghipour, C. Gisselbrecht, P. Mazza, E. Montserrat, N. Niederwieser, K. Indrak, A. Kolbe, P. Biron, A. Levis, A. Goldstone, N. Schmitz
Journal: Blood (2007)
Clinical, Biological, and Molecular Characteristics of Well-Differentiated Systemic Mastocytosis: a study in 18 Patients by Spanish Network on Mastocytosis (REMA)
Authors: Iván Alvarez-Twose, Laura Sánchez-Muñoz, María Jara-Acevedo, Cristina Teodosio, Andrés García-Montero, Mónica García-Cosio, Manuela Mollejo, Alberto Orfao, Luis María Escribano
Journal: Blood (2008)
Interleukin-10 family cytokines pathway: genetic variants and psoriasis
Authors: E. Galimova, R. Rätsep, T. Traks, K. Kingo, V. Escott-Price, S. Kõks
Journal: British Journal of Dermatology (2017)

Interleukin (IL)‐10 family cytokines IL‐10, IL‐19, IL‐20 and IL‐24 have been implicated in autoimmune diseases and we have previously reported that genetic variants in the IL10 gene cluster were associated with psoriasis. To analyse the relationship between genetic polymorphisms in the IL10 gene cluster and psoriasis. This study also explores whether there are gene–gene interactions among these genetic polymorphisms. A total of 377 patients with psoriasis and 403 matched healthy controls were enrolled to carry out a case–control study for 48 single‐nucleotide polymorphisms (SNPs) of the IL10 gene cluster. Genotyping for the SNPs was conducted on the Applied Biosystems 3730 DNA Analyzer using SNPlex® technology. Generalized multifactor dimensionality reduction (GMDR) analysis was applied to discover a likely gene–gene interaction model among the SNPs. The results showed that the allele distributions of IL10 gene cluster SNPs are significantly different between the case and control groups. Carriers of the IL10 T allele (rs1554286) and the IL20 T allele (rs1400986) conferred protection from psoriasis [odds ratio (OR) = 0·63, corrected P‐value (Pc) = 0·007; OR = 0·62, Pc = 0·038, respectively]. GMDR analysis displayed a significant gene–gene interaction between IL10 (rs1554286) and IL20 (rs1518108) variants. The strongest protective effect was found with the block 1 haplotype ACATA in the IL10 gene (Pc = 0·004). This study presents a novel finding that the combination of the two SNPs, IL10 (rs1554286) and IL20 (rs1518108), is associated with a reduced risk of psoriasis. Our results indicate that genetic variants of the immunomodulatory IL10 and IL20 genes may offer a protective effect in Europeans from Russia. Independent studies are required to verify the results and find a possible functional explanation.
Combination of Anti-Rh(D) and Danazol in Patients with Immune Thrombocytopenia
Authors: Mala Varma, Ilan Shapira, Ibrahim Nakhoul, Jonah Shulman, David Lucido, Peter Kozuch, Bruce Culliney, Tahir Mirzoyev, Maria Machuca, Michael L. Grossbard
Journal: Blood (2012)
Barth syndrome cardiomyopathy
Authors: Jan Dudek, Christoph Maack
Journal: Cardiovascular Research (2017)

Barth syndrome (BTHS) is an inherited form of cardiomyopathy, caused by a mutation within the gene encoding the mitochondrial transacylase tafazzin. Tafazzin is involved in the biosynthesis of the unique phospholipid cardiolipin (CL), which is almost exclusively found in mitochondrial membranes. CL directly interacts with a number of essential protein complexes in the mitochondrial membranes including the respiratory chain, mitochondrial metabolite carriers, and proteins, involved in shaping mitochondrial morphology. Here we describe, how in BTHS CL deficiency causes changes in the morphology of mitochondria, structural changes in the respiratory chain, decreased respiration, and increased generation of reactive oxygen species. A large number of cellular and animal models for BTHS have been established to elucidate how mitochondrial dysfunction induces sarcomere disorganization and reduced contractility, resulting in dilated cardiomyopathy in vivo.
Ibrutinib Responsive Micro-RNAs and Upregulation of Tumor Suppressor Targets in Chronic Lymphocytic Leukemia
Authors: Layla M Saleh, Weixin Wang, Sarah E. M. Herman, Mohammed Farooqui, Clare Sun, Emily Barber, Meghan Corrigan-Cummins, Nakhle Saba, Hasan Awad, Adrian Wiestner, Katherine R. Calvo
Journal: Blood (2015)
Musashi RNA-Binding Proteins as Cancer Drivers and Novel Therapeutic Targets
Authors: Alexander E. Kudinov, John Karanicolas, Erica A. Golemis, Yanis Boumber
Journal: Clinical Cancer Research (2017)

Aberrant gene expression that drives human cancer can arise from epigenetic dysregulation. Although much attention has focused on altered activity of transcription factors and chromatin-modulating proteins, proteins that act posttranscriptionally can potently affect expression of oncogenic signaling proteins. The RNA-binding proteins (RBP) Musashi-1 (MSI1) and Musashi-2 (MSI2) are emerging as regulators of multiple critical biological processes relevant to cancer initiation, progression, and drug resistance. Following identification of Musashi as a regulator of progenitor cell identity in Drosophila, the human Musashi proteins were initially linked to control of maintenance of hematopoietic stem cells, then stem cell compartments for additional cell types. More recently, the Musashi proteins were found to be overexpressed and prognostic of outcome in numerous cancer types, including colorectal, lung, and pancreatic cancers; glioblastoma; and several leukemias. MSI1 and MSI2 bind and regulate the mRNA stability and translation of proteins operating in essential oncogenic signaling pathways, including NUMB/Notch, PTEN/mTOR, TGFβ/SMAD3, MYC, cMET, and others. On the basis of these activities, MSI proteins maintain cancer stem cell populations and regulate cancer invasion, metastasis, and development of more aggressive cancer phenotypes, including drug resistance. Although RBPs are viewed as difficult therapeutic targets, initial efforts to develop MSI-specific inhibitors are promising, and RNA interference-based approaches to inhibiting these proteins have had promising outcomes in preclinical studies. In the interim, understanding the function of these translational regulators may yield insight into the relationship between mRNA expression and protein expression in tumors, guiding tumor-profiling analysis. This review provides a current overview of Musashi as a cancer driver and novel therapeutic target. Clin Cancer Res; 23(9); 2143-53. ©2017 AACR.
Lysine Acetylation and Deacetylation in Brain Development and Neuropathies
Authors: Alicia Tapias, Zhao-Qi Wang
Journal: Genomics Proteomics & Bioinformatics (2017)

Abstract Embryonic development is critical for the final functionality and maintenance of the adult brain. Brain development is tightly regulated by intracellular and extracellular signaling. Lysine acetylation and deacetylation are posttranslational modifications that are able to link extracellular signals to intracellular responses. A wealth of evidence indicates that lysine acetylation and deacetylation are critical for brain development and functionality. Indeed, mutations of the enzymes and cofactors responsible for these processes are often associated with neurodevelopmental and psychiatric disorders. Lysine acetylation and deacetylation are involved in all levels of brain development, starting from neuroprogenitor survival and proliferation, cell fate decisions, neuronal maturation, migration, and synaptogenesis, as well as differentiation and maturation of astrocytes and oligodendrocytes, to the establishment of neuronal circuits. Hence, fluctuations in the balance between lysine acetylation and deacetylation contribute to the final shape and performance of the brain. In this review, we summarize the current basic knowledge on the specific roles of lysine acetyltransferase (KAT) and lysine deacetylase (KDAC) complexes in brain development and the different neurodevelopmental disorders that are associated with dysfunctional lysine (de)acetylation machineries.
Bendamustine (Treanda®), Etoposide and Dexamethasone (BED) Followed by GCSF Effectively Mobilizes Autologous Peripheral Blood Hematopoietic Stem Cells
Authors: Damian J. Green, William I. Bensinger, Leona Holmberg, Theodore A. Gooley, Brian G. Till, Lihua Elizabeth Budde, Shani L. Frayo, Jennifer E. Roden, Lacey Hedin, Oliver W. Press, Ajay K. Gopal
Journal: Blood (2012)
Treatment of Early Stage Nodal Follicular Lymphoma Using Involved-Field Radiotherapy and Rituximab: Preliminary Results of the Mir Trial (phase II study of the German Low Grade Lymphoma Study Group (GLSG))
Authors: Klaus Herfarth, Marianne Engelhard, Peter Borchmann, Karin Hohloch, Volker Budach, Andreas Viardot, Mathias Witzens-Harig, Hans Eich, Wolfgang Hiddemann, Martin Dreyling
Journal: Blood (2012)
Tumor shrinkage and overall survival (OS) from multicenter phase II study of modified FOLFOX7 (combination chemotherapy of infusional 5-FU/l-leucovorin and intermittent oxaliplatin) with bevacizumab in the first-line therapy of colorectal cancer: CRAFT trial.
Authors: Keiji Koda, Hideyuki Ishida, Ryoji Katoh, Kotaro Maeda, Toru Tezuka, Hideyuki Mishima, Naohiro Tomita, Norio Saito, Chikuma Hamada, Junichi Sakamoto
Journal: Journal of Clinical Oncology (2012)

616 Background: Additional bevacizumab (BV) to FOLFOX has been established as a standard 1st-line therapy for mCRC. The intermittent administration of L-OHP can reduce the peripheral sensory neurotoxicity as reported in OPTIMOX and CONcePT study. CRAFT trial was conducted to confirm the effectiveness of stop and go strategy of mFOLFOX7+BV. We previously reported the feasibility and good progression free survival (PSF) in that study (K. Ishibashi et al. ECCO2011). This time, the overall survival (OS) and possibilities for conversion surgery were reported. Methods: We administered 8cycles of mFOLFOX7/BV followedby 8 cycles of FULV/BV as a maintenance, and reintroduction of 8 cycles of mFOLFOX7/BV until disease progression. Patients who had progressive disease during maintenance phase are allowed to receive oxaliplatin ahead of schedule. The primary endpoint is the duration from the study enrollment to disease progression (PFS I). The secondary endpoints are survival time from the study enrollment to disease progression or death plus from 1 st PD in the maintenance phase to 2 nd PD (PFS II), tme to treatment failure (TTF) ,OS, and safety. Results: Between March 2009 and June 2010, 52pts were enrolled. Median PFS I was 13.2 (95%CI,10.3-15.0) months. PFS II was 13.5(95%CI,12.5-15.1) months. Median, TTF was 10.3 (95%CI, 5.6-12.1) months, OS was 27.4 (95%CI, 21.0-32.8) months. There was no uncontrollable toxicity. The range of tumor shrinkage wasup to - 91.0% and 3 patients received conversion surgery. Conclusions: This study met its primary endpoint PFS I (K.Ishibashi et al. ECCO 2011.). The current data indicated that stop and go strategy is effective to prolong the duration of 1 st line treatment and to improve survival in mCRC. Tumor shrinkage data also suggested mFOLFOX7+BV has possibilities to make a conversion surgery. Water fall plot for all patients will be presented at the meeting.
An Outcome Study On Survival and Disease Control in Patients with High-Risk Multiple Myeloma (MM) for Relapse, Treated with High-Dose Melphalan Combined with Bortezomib for Autotransplant Followed by Post-Transplant Maintenance with Bortezomib and Lenalidomide.
Authors: Choon Kee Lee, Jeff Kaiser, Han Myint, Mary Berg, J. Fred Kolhouse, William Robinson
Journal: Blood (2009)
Palmitoylation Controls Death Receptor Function in Chronic Lymphocytic Leukemia
Authors: Lukas P. Frenzel, Valeska Feldhaus, Marion Rusch, Reinhild Brinker, Julia Claasen, Christian P. Pallasch, Herbert Waldmann, Michael Hallek, Christian Hedberg, Clemens-Martin Wendtner
Journal: Blood (2011)
Rituximab-Mediated Antibody-Dependent Cellular Cytotoxicity Is Enhanced by Interleukin-15 or CpG Oligodeoxynucleotides.
Authors: Esther Moga, Javier Briones, Eva Alvarez, Elisabet Cantó, Silvia Vidal, José Luís Rodríguez-Sánchez, Jordi Sierra
Journal: Blood (2005)
Favourable Outcome of Pregnancy in Essential Thrombocythemia (ET) Patients Treated with Interferon Alpha. A Report from the Registro Italiano Trombocitemia (RIT).
Authors: Lorella Melillo, Daniela Valente, Alessia Tieghi, Anna Candoni, Bruno Martino, Rosanna Ciancia, Vincenzo Martinelli, Franca Radaelli, Giorgina Specchia, Roberto Latagliata, Potito R. Scalzulli, Fausto Palmieri, Michele Cedrone, Nicola Cascavilla, Luigi Gugliotta
Journal: Blood (2007)
Reduced-Intensity Conditioning Regimen in Allogeneic Haematopoietic Stem Cell Transplantation for Follicular Lymphoma and Chronic Lymphocytic Leukemia
Authors: Carlos Pinho Vaz, Rosa Branca Ferreira, Joao Silva, Isabel Barbosa, Susana Roncon, Alzira Carvalhais, A. Martinho, Fernando Campilho, Antonio Campos
Journal: Blood (2008)
Independent Validation of Prognostic Relevance of a Previously Reported Gene-Expression Signature in Acute Myeloid Leukemia (AML) with Normal Cytogenetics (NC): A Cancer and Leukemia Group B (CALGB) Study.
Authors: Guido Marcucci, M. D. Radmacher, A. S. Ruppert, K. Mrózek, J. E. Kolitz, S. P. Whitman, C. G. Edwards, J. W. Vardiman, M. A. Caligiuri, A. J. Carroll, R. A. Larson, C. D. Bloomfield
Journal: Blood (2005)
Karyotypic and Molecular Cytogenetic Findings in Childhood T-Cell Acute Lymphoblastic Leukemia (ALL): The Schneider Children’s Medical Center of Israel (SCMCI) Experience
Authors: Bati a Stark, Marta Jeison, Jaquelina Heker, Jacques Mardoukh, Gili Halevi-Berko, Drorit Luria, Gali Avrahami, Jerry Stein, Isaac Yaniv
Journal: Blood (2008)
Tumor Necrosis Factor Alfa (TNFα), Lymphotoxin Alfa (Ltα) and Interleukin-6 (IL-6) Polymorphisms in Brazilian Multiple Myeloma (MM) Patients.
Authors: Cibele R. Duch, Maria S. Figueiredo, Manuella S.S. Almeida, Christian Ribas, Gisele W.B. Colleoni, José O. Bordin
Journal: Blood (2004)
GPs' responsibility for midwives' actions
Authors: C. Flint
Journal: BMJ (1996)

haemophilia data that cannot establish correlation or cause.Duesberg has argued against these data and against mistaking correlation for causality,2 3 but this review fails to mention these arguments and makes no effort to convey the breadth and depth of the reviews collected in the book.Finally, I agree with Derbyshire: Duesberg has been mistreated.What Peter Duesberg has been arguing for-more research on substances known or suspected to be immunosuppressive-should not be controversial, it should be welcomed.Iftrue, then Duesberg should be taken seriously and not, as Derbyshire suggests, placed "peripheral to the mainstream AIDS debate ... as a maverick rather than as a heretic."That debate would be impoverished or non-existent were it not for Duesberg's persistent scientific criticisms over 10 years.Derbyshire cannot have it both ways where a serious critic with something constructive to offer is also marginalised and mistreated by our AIDS leadership.
RARE-05BIFRONTAL OSTEOMA IN CONJUNCTION WITH CALVARIUM HEMANGIOMA: FIRST REPORTED CASE
Authors: Mansour Mathkour, Juanita Garces, Joshua Hanna, Marcus Ware
Journal: Neuro-Oncology (2015)

INTRODUCTION: Osteomas are benign osteogenic neoplasms of cancellous bone that typically occur in the head and neck as a single lesion. They may be central, peripheral or extra-skeletal and typically involve the frontal sinus. Hemangiomas are exceedingly rare benign tumors that arise from intra-skeletal vasculature. They are typically located in the vertebral body with calvarium involvement occurring less commonly. To our knowledge, no prior cases have been reported in the literature of bifrontal bone osteoma that co-occurs with frontal bone hemangioma. CASE: A 65-year-old female presented with a 4-month history of a painless mass developing over her right eyebrow. On physical exam patient had a nonpainful immobile growth. Magnetic Resonance Imaging (MRI) revealed a peripheral enhancing mass of the right frontal calvarium without breach apparent to the inner or outer table or sinus involvement. Computed Topographic (CT) imaging showed a mixed density, expansile lesion consistent with a hemangioma inside the right frontal calvarium. The patient underwent a bifrontal craniectomy where the hemangioma was resected in conjunction with the second bony lesion. Pathology results confirmed a frontal osteoma in conjunction with a hemangioma of the calvarium. The patient underwent an uncomplicated clinical course with no adjuvant therapy. The patient is presently 4 months post-operation with no evidence of recurrence. CONCLUSION: Osteomas rarely occur as multiple lesions, especially in the absence of sinus involvement. In similar tone, hemangiomas themselves are rare lesions, with calvarium origin reported as a less common location. Both osteoma and hemangioma are benign lesions and treatment for each alone is surgical excision without the need of adjuvant therapies. As such, this coincidence of lesions is unprecedented, making it difficult to determine the clinical or prognostic significance of this patient's presentation and treatment outcomes.